The Rollercoaster Ride of Hope and Dilution: Galmed's Cancer Breakthrough Sends Stock Soaring—But What About the Small Guys?
A New Dawn for Epilepsy Patients: Rapport's Promising Drug Advances to Phase 3 Trials